ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The allele ɛ4 of apolipoprotein E (apoE4) is the most prevalent genetic risk factor for Alzheimer's disease (AD) and is therefore a promising therapeutic target. Human and animal model studies suggest that apoE4 is hypolipidated; accordingly, we have previously shown that the retinoid X receptor (RXR) agonist bexarotene upregulates ABCA1, the main apoE-lipidating protein, resulting in increased lipidation of apoE4, and the subsequent reversal of the pathological effects of apoE4, namely: accumulation of Aβ42 and hyperphosphorylated tau, as well as reduction in the levels of synaptic markers and cognitive deficits. Since the RXR system has numerous other targets, it is important to devise the means of activating ABCA1 selectively. We presently utilized CS-6253, a peptide shown to directly activate ABCA1 in vitro, and examined the extent to which it can affect the degree of lipidation of apoE4 in vivo and counteract the associated brain and behavioral pathologies. This revealed that treatment of young apoE4-targeted replacement mice with CS-6253 increases the lipidation of apoE4. This was associated with a reversal of the apoE4-driven Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as of the synaptic impairments and cognitive deficits. These findings suggest that the pathological effects of apoE4 in vivo are associated with decreased activation of ABCA1 and impaired lipidation of apoE4 and that the downstream brain-related pathology and cognitive…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“peptide mimetics used to upregulate ABCA1 were shown to increase APOE4 lipidation and reduce Aβ deposition and cognitive deficits in APOE4 knock-in (but not APOE3 knock-in) plaque-depositing mice, indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“indicating that directly targeting APOE lipidation is an effective therapeutic approach212”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [212]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
In the citing paper
“Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87].”
From Apoe4 and Alzheimer’s Disease Pathogenesis—Mitochondrial Deregulation and Targeted Therapeutic Strategies (2023) · cites this paper as [87]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“Genetic studies of sporadic Alzheimer’s disease (AD) and of families with late onset AD revealed that the allele APOE (cid:2) 4 (apoE4) is a genetic risk factor for AD [1–3].”
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
ApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · cited 1×
“:+9723 6409624;Fax:+97236406356;E-mail:dmichael@post.tau.ac.il. allele, which renders it the most prevalent genetic risk factor for AD [2].”
Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
Pitas, R. E., Boyles, J. K., Lee, S. H., Foss, D., & Mahley, R. W. (1987) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(87)90295-5 · Cited by 693 · cited 1×
“…CS-6253 accumulates in the brain and co-localizes with astrocytes, which are enriched with ABCA1 and are the major source of brain apoE [15, 38, 39] was assessed immunohistochemically by double staining of the hippocampus utilizing the anti-CS-6253 Ab and an Ab directed at the astrocytic…”
LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes
Laffitte, B. A., Repa, J. J., Joseph, S. B., Wilpitz, D. C., Kast, H. R., Mangelsdorf, D. J., & Tontonoz, P. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.507 · Cited by 683
Alzheimer’s disease: the cholesterol connection
Puglielli, L., Tanzi, R. E., & Kovacs, D. M. (2003) · Nature Neuroscience · doi:10.1038/nn0403-345 · Cited by 677
Sullivan, P. M., Mezdour, H., Aratani, Y., Knouff, C., Najib, J., Reddick, R. L., Quarfordt, S. H., & Maeda, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17972 · Cited by 575 · cited 1×
“[24].”
Strittmatter, W. J., Saunders, A. M., Goedert, M., Weisgraber, K. H., Dong, L. M., Jakes, R., Huang, D. Y., Pericak-Vance, M., Schmechel, D., & Roses, A. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11183 · Cited by 474
Wahrle, S. E., Jiang, H., Parsadanian, M., Legleiter, J., Han, X., Fryer, J. D., Kowalewski, T., & Holtzman, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407963200 · Cited by 474
Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain
Hirsch-Reinshagen, V., Zhou, S., Burgess, B. L., Bernier, L., McIsaac, S. A., Chan, J. Y., Tansley, G. H., Cohn, J. S., Hayden, M. R., & Wellington, C. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407962200 · Cited by 385 · cited 1×
“ABCG1, respectively) [14, 15].”
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
Riddell, D. R., Zhou, H., Atchison, K., Warwick, H. K., Atkinson, P. J., Jefferson, J., Xu, L., Aschmies, S., Kirksey, Y., Hu, Y., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1972-08.2008 · Cited by 346 · cited 2×
“As can be seen, and in accordance with previous studies [13, 21, 30, 40], the total apoE levels of the apoE4 mice were lower than that of the correspond-”
TOKUDA, T., CALERO, M., MATSUBARA, E., VIDAL, R., KUMAR, A., PERMANNE, B., ZLOKOVIC, B., SMITH, J. D., LADU, M. J., ROSTAGNO, A., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480359 · Cited by 272
Michikawa, M., Fan, Q., Isobe, I., & Yanagisawa, K. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741008.x · Cited by 244 · cited 1×
“Furthermore, apoE4 is markedly less potent than apoE3 in promoting the efflux of cholesterol and phospholipids from both astrocytes and neurons in culture [11–13].”
Role of ATP‐binding cassette transporters in brain lipid transport and neurological disease
Kim, W. S., Weickert, C. S., & Garner, B. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05099.x · Cited by 238
DeMattos, R. B., Brendza, R. P., Heuser, J. E., Kierson, M., Cirrito, J. R., Fryer, J., Sullivan, P. M., Fagan, A. M., Han, X., & Holtzman, D. M. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00049-3 · Cited by 180
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161
Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02183.x · Cited by 160
Formation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Levi, O., Jongen-Relo, A. L., Feldon, J., Roses, A. D., & Michaelson, D. M. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00045-7 · Cited by 145
Self-citationBour, A., Grootendorst, J., Vogel, E., Kelche, C., Dodart, J.-C., Bales, K., Moreau, P.-H., Sullivan, P. M., & Mathis, C. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.008 · Cited by 141
Rodriguez, G. A., Burns, M. P., Weeber, E. J., & Rebeck, G. W. (2013) · Learning & Memory · doi:10.1101/lm.030031.112 · Cited by 137
Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene
Boehm-Cagan, A., & Michaelson, D. M. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5198-13.2014 · Cited by 134
Self-citationBielicki, J. K., Zhang, H., Cortez, Y., Zheng, Y., Narayanaswami, V., Patel, A., Johansson, J., & Azhar, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m003665 · Cited by 127
Self-citationExpression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia
Karten, B., Campenot, R. B., Vance, D. E., & Vance, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508915200 · Cited by 124
Liraz, O., Boehm-Cagan, A., & Michaelson, D. M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-16 · Cited by 118
Self-citationReduced levels of human apoE4 protein in an animal model of cognitive impairment
Sullivan, P. M., Han, B., Liu, F., Mace, B. E., Ervin, J. F., Wu, S., Koger, D., Paul, S., & Bales, K. R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.011 · Cited by 113
He, X., Cooley, K., Chung, C. H. Y., Dashti, N., & Tang, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3993-06.2007 · Cited by 107
ABCA1 dimer–monomer interconversion during HDL generation revealed by single-molecule imaging
Nagata, K. O., Nakada, C., Kasai, R. S., Kusumi, A., & Ueda, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220703110 · Cited by 103
Hanson, A. J., Bayer-Carter, J. L., Green, P. S., Montine, T. J., Wilkinson, C. W., Baker, L. D., Watson, G. S., Bonner, L. M., Callaghan, M., Leverenz, J. B., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.396 · Cited by 102
Belinson, H., Lev, D., Masliah, E., & Michaelson, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5633-07.2008 · Cited by 101 · cited 4×
“1; Media Cybernetics), as described previously [28].”
InfluentialSelf-citationUnifying Candidate Gene and GWAS Approaches in Asthma
Michel, S., Liang, L., Depner, M., Klopp, N., Ruether, A., Kumar, A., Schedel, M., Vogelberg, C., von Mutius, E., von Berg, A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013894 · Cited by 96
Levi, O., & Michaelson, D. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04189.x · Cited by 94
Self-citationMinagawa, H., Gong, J., Jung, C., Watanabe, A., Lund‐Katz, S., Phillips, M. C., Saito, H., & Michikawa, M. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.22073 · Cited by 90 · cited 1×
“Furthermore, apoE4 is markedly less potent than apoE3 in promoting the efflux of cholesterol and phospholipids from both astrocytes and neurons in culture [11–13].”
Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in Vivo
Tai, L. M., Koster, K. P., Luo, J., Lee, S. H., Wang, Y.-T., Collins, N. C., Ben Aissa, M., Thatcher, G. R. J., & LaDu, M. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.600833 · Cited by 89
Sex- and APOE Isoform-Dependent Effects of Radiation on Cognitive Function
Villasana, L., Acevedo, S., Poage, C., & Raber, J. (2006) · Radiation Research · doi:10.1667/rr0642.1 · Cited by 74
Lalloyer, F., Pedersen, T. A., Gross, B., Lestavel, S., Yous, S., Vallez, E., Gustafsson, J.-A., Mandrup, S., Fiévet, C., Staels, B., et al. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.189506 · Cited by 73
Characterization of Oligomeric Human ATP Binding Cassette Transporter A1
Denis, M., Haidar, B., Marcil, M., Bouvier, M., Krimbou, L., & Genest, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406881200 · Cited by 73
Hafiane, A., Bielicki, J. K., Johansson, J. O., & Genest, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0131997 · Cited by 57
Self-citationRescuing effects of RXR agonist bexarotene on aging-related synapse loss depend on neuronal LRP1
Tachibana, M., Shinohara, M., Yamazaki, Y., Liu, C.-C., Rogers, J., Bu, G., & Kanekiyo, T. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2015.12.003 · Cited by 57
Trompier, D., Alibert, M., Davanture, S., Hamon, Y., Pierres, M., & Chimini, G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601072200 · Cited by 48
Adeosun, S. O., Hou, X., Zheng, B., Stockmeier, C., Ou, X., Paul, I., Mosley, T., Weisgraber, K., & Wang, J. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497909 · Cited by 44
Belinson, H., & Michaelson, D. M. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0218-9 · Cited by 44
Self-citationRNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment
Lefterov, I., Schug, J., Mounier, A., Nam, K. N., Fitz, N. F., & Koldamova, R. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.019 · Cited by 36
Ito, J.-I., Nagayasu, Y., Miura, Y., Yokoyama, S., & Michikawa, M. (2014) · Brain Research · doi:10.1016/j.brainres.2014.04.037 · Cited by 35
Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice
Salomon-Zimri, S., Boehm-Cagan, A., Liraz, O., & Michaelson, D. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354777 · Cited by 34 · cited 4×
“This revealed, in accordance with previous observations in different spatial learning and memory paradigms [33, 35–37], that the apoE4 control mice took longer to learn the location of the platform compared to the control apoE3 mice, and that the CS-6253 treatment significantly improved the per-1224…”
InfluentialSelf-citationInvolvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo
Gilat-Frenkel, M., Boehm-Cagan, A., Liraz, O., Xian, X., Herz, J., & Michaelson, D. (2014) · Current Alzheimer Research · doi:10.2174/1567205010666131119232444 · Cited by 32
Self-citationSalomon‐Zimri, S., Liraz, O., & Michaelson, D. M. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2014.11.014 · Cited by 19
Self-citationHaas, A., Liraz, O., & Michaelson, D. M. (2012) · Neurodegenerative Diseases · doi:10.1159/000334902 · Cited by 11
Self-citationFocusing on ApoE: a viable strategy for Alzheimer therapy
Michaelson, D. M., Boehm‐Cagan, A., & Luz, I. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.01.089 · Cited by 1
Self-citation
Research works printed but not linked: 1
- Salomon-Zimri, 2015, Behavioral testing affects the phenotypic expression of APOE ɛ3 and APOE ɛ4 in targeted replacement mice and reduces the differences between them, Alzheimers Dement (Amst), 1, 127, 10.1016/j.dadm.2014.11.014 · DOI
Cited by
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“Peptide mimetics used to upregulate ABCA1 have been shown to increase apoE4 lipidation, and reduce Aβ, tau, and cognitive deficits in a mouse model [207].”
BackgroundApoE4: an emerging therapeutic target for Alzheimer’s disease
Safieh, M., Korczyn, A. D., & Michaelson, D. M. (2019) · BMC Medicine · doi:10.1186/s12916-019-1299-4 · Cited by 449
Self-citationYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease
Marais, A. D. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.002 · Cited by 382
Metadata
- Authors
- Boehm-Cagan, A., Bar, R., Liraz, O., Bielicki, J. K., Johansson, J. O., & Michaelson, D. M.
- Affiliations
- The Department of Neurobiology, The George S. Wise Faculty of Life Sciences, The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel
- Tel Aviv University (IL)
- Lawrence Berkeley National Laboratory (US)
- Artery Therapeutics, Inc., San Ramon, CA, USA
- Corresponding author
- Michaelson, Daniel M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2016-10-04
- Volume
- 54
- Issue
- 3
- Pages
- 1219-1233
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2516112233
- Cited by
- 116
- References
- 52
- Citations by year
- 2026: 2 · 2025: 17 · 2024: 19 · 2023: 11 · 2022: 15 · 2021: 16 · 2020: 11 · 2019: 8 · 2018: 4 · 2017: 11 · 2016: 2
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ABCA1, APOE ε4
- MeSH terms
- Animals, Brain, Cognition Disorders, Male, Mice, Inbred C57BL, Mice, Transgenic, Peptides, Mice, Apolipoprotein E4, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.